Adhera Therapeutics (MRNA):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Adhera Therapeutics (MRNA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9908
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:58
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Adhera Therapeutics (Adhera) is a nucleic acid-based drug discovery and development company that focuses on rare diseases. It focuses on treating the intersection of arthritis, hypertension, pain, and cancer using combination therapies of already approved drugs. The company is developing and commercializing late stage, non-addictive pain therapeutics. Based on its drug discovery platform, SMARTICLES Adhera develops proprietary single and double-stranded nucleic acid therapeutics including microRNA mimics, siRNAs, antagomirs and antisense compounds envisioned to activate various RNA-based mechanisms of action. The company is developing CEQ508 in Phase I clinical studies for treating patients with familial adenomatous polyposis (FAP). Adhera is headquartered in City of Industry, California, the US.

Adhera Therapeutics (MRNA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Adhera Therapeutics, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Marina Biotech Acquires Prestalia from Symplmed Pharma 12
Marina Biotech to Acquire Intranasal Ketamine Program from Turing Pharma 13
Venture Financing 14
Marina Biotech Raises USD0.3 Million in Financing Round 14
Partnerships 15
Rosetta Genomics And Marina Biotech Enter Into Agreement To Develop MicroRNA Diagnostics 15
Marina Biotech Enters Into Co-Development Agreement With Girindus 17
Merger 18
Marina Biotech and IthenaPharma Merges 18
Licensing Agreements 19
Marina Biotech Enters into Development and Licensing Agreement with Autotelic 19
Oncotelic Enters into Licensing Agreement with Marina Biotech 20
LipoMedics Enters into Licensing Agreement Marina Biotech for SMARTICLES 21
Autotelic Enters into Licensing Agreement with Marina Biotech 22
Marina Biotech Enters into Licensing Agreement with Autotelic 23
Marina Biotech Enters into Licensing Agreement for NOV582 24
Marina Biotech Exercises Option for Licensing Agreement for Smarticles and DiLA2 Platform 25
Hongene Biotech Enters into Licensing Agreement with Marina Biotech 26
Marina Biotech Enters into Licensing Agreement with MiNA Therapeutics 27
Marina Biotech Amends Licensing Agreement with Mirna Therapeutics for MicroRNA Therapeutics 28
Arcturus Therapeutics Enters Into Licensing Agreement With Marina Biotech For Unlocked Nucleobase Analog Technology 30
Marina Biotech Enters Into Licensing Agreement With Tekmira Pharma For RNAi Technology 31
Marina Biotech Enters Into Licensing Agreement With Novartis For CRN Technology 32
Marina Biotech Enters Into Licensing Agreement With ProNAi Therapeutics For DNAi Therapeutics 33
Equity Offering 34
Marina Biotech Raises USD11.7 Million in Private Placement 34
Marina Biotech Raises USD0.3 Million in Private Placement of Shares 35
Marina Biotech Raises USD1 Million in Private Placement of Preferred Stock and Warrants 36
Marina Biotech Raises USD6 Million in Private Placement Of Shares 37
Marina Biotech Raises USD1.2 Million in Private Placement of Shares and Warrants 38
Marina Biotech Completes Private Placement Of Shares For US$2 Million 39
Marina Biotech Completes Private Placement Of Redeemable Preferred Stock For US$5 Million 40
Debt Offering 41
Marina Biotech to Raise USD0.5 Million in Private Placement of Notes Due 2018 41
Marina Biotech Raises USD0.2 Million in Private Placement of 5% Notes Due 2018 42
Marina Biotech Raises USD0.1 Million in Issue of Convertible Promissory Notes 43
Asset Transactions 44
Marina Biotech to Sell DiLA2 Delivery Platform for USD1.5 Million 44
Adhera Therapeutics – Key Competitors 45
Adhera Therapeutics – Key Employees 46
Adhera Therapeutics – Locations And Subsidiaries 47
Head Office 47
Other Locations & Subsidiaries 47
Recent Developments 48
Corporate Communications 48
Aug 06, 2018: Marina Biotech appoints Jay D. Schwartz to serve as senior vice president, commercial operations 48
Jun 29, 2018: Marina Biotech Names Uli Hacksell And Robert C. Moscato As Board Directors 49
Jun 20, 2018: Marina Biotech Appoints Robert Moscato to Chief Executive Officer 50
Jul 05, 2017: Marina Biotech Announces the Appointment of Dr. Vuong Trieu as Executive Chairman 51
Jun 26, 2017: Marina Biotech appoints chief commercial officer 52
Feb 21, 2017: Marina Biotech Appoints Dr. Seymour Fein as Chief Medical Officer 53
Feb 14, 2017: Marina Biotech Announces Key Additions to its Executive Management Team 54
Product News 55
03/13/2017: Marina Biotech to Present A Late Breaking Poster on the Safety and Tolerability of CEQ508 for FAP at the Society of Toxicology 56th Annual Meeting on March 16 55
Other Significant Developments 56
Apr 05, 2017: Marina Biotech Provides Business Update 56
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58

List of Tables
Adhera Therapeutics, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Adhera Therapeutics, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Adhera Therapeutics, Deals By Therapy Area, 2012 to YTD 2018 9
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Marina Biotech Acquires Prestalia from Symplmed Pharma 12
Marina Biotech to Acquire Intranasal Ketamine Program from Turing Pharma 13
Marina Biotech Raises USD0.3 Million in Financing Round 14
Rosetta Genomics And Marina Biotech Enter Into Agreement To Develop MicroRNA Diagnostics 15
Marina Biotech Enters Into Co-Development Agreement With Girindus 17
Marina Biotech and IthenaPharma Merges 18
Marina Biotech Enters into Development and Licensing Agreement with Autotelic 19
Oncotelic Enters into Licensing Agreement with Marina Biotech 20
LipoMedics Enters into Licensing Agreement Marina Biotech for SMARTICLES 21
Autotelic Enters into Licensing Agreement with Marina Biotech 22
Marina Biotech Enters into Licensing Agreement with Autotelic 23
Marina Biotech Enters into Licensing Agreement for NOV582 24
Marina Biotech Exercises Option for Licensing Agreement for Smarticles and DiLA2 Platform 25
Hongene Biotech Enters into Licensing Agreement with Marina Biotech 26
Marina Biotech Enters into Licensing Agreement with MiNA Therapeutics 27
Marina Biotech Amends Licensing Agreement with Mirna Therapeutics for MicroRNA Therapeutics 28
Arcturus Therapeutics Enters Into Licensing Agreement With Marina Biotech For Unlocked Nucleobase Analog Technology 30
Marina Biotech Enters Into Licensing Agreement With Tekmira Pharma For RNAi Technology 31
Marina Biotech Enters Into Licensing Agreement With Novartis For CRN Technology 32
Marina Biotech Enters Into Licensing Agreement With ProNAi Therapeutics For DNAi Therapeutics 33
Marina Biotech Raises USD11.7 Million in Private Placement 34
Marina Biotech Raises USD0.3 Million in Private Placement of Shares 35
Marina Biotech Raises USD1 Million in Private Placement of Preferred Stock and Warrants 36
Marina Biotech Raises USD6 Million in Private Placement Of Shares 37
Marina Biotech Raises USD1.2 Million in Private Placement of Shares and Warrants 38
Marina Biotech Completes Private Placement Of Shares For US$2 Million 39
Marina Biotech Completes Private Placement Of Redeemable Preferred Stock For US$5 Million 40
Marina Biotech to Raise USD0.5 Million in Private Placement of Notes Due 2018 41
Marina Biotech Raises USD0.2 Million in Private Placement of 5% Notes Due 2018 42
Marina Biotech Raises USD0.1 Million in Issue of Convertible Promissory Notes 43
Marina Biotech to Sell DiLA2 Delivery Platform for USD1.5 Million 44
Adhera Therapeutics, Key Competitors 45
Adhera Therapeutics, Key Employees 46
Adhera Therapeutics, Subsidiaries 47

List of Figures
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Adhera Therapeutics (MRNA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Dongbu Insurance Co., Ltd.:企業の戦略・SWOT・財務情報
    Dongbu Insurance Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Dongbu Insurance Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Citic Resources Holdings Limited
    Citic Resources Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Citic Resources Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Keikyu Corporation:企業の戦略・SWOT・財務情報
    Keikyu Corporation - Strategy, SWOT and Corporate Finance Report Summary Keikyu Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Windtree Therapeutics Inc (WINT):製薬・医療:M&Aディール及び事業提携情報
    Summary Windtree Therapeutics Inc (Windtree Therapeutics), formerly Discovery Laboratories, Inc. is a specialty biotechnology company. It focuses on the development of novel KL4 surfactant therapies for patients with respiratory diseases and other potential applications. The company’s lead developme …
  • Vectura Group Plc (VEC)-医療機器分野:企業M&A・提携分析
    Summary Vectura Group Plc (Vectura) is a formulation and device business for inhaled airways products providing an integrated inhaled drug delivery platform. It develops inhalation products, to help patients suffering from airways diseases such as asthma, chronic obstructive pulmonary disease (COPD) …
  • U.S. HealthWorks Medical Group-製薬・医療分野:企業M&A・提携分析
    Summary U.S. HealthWorks Medical Group (U.S. HealthWorks), a subsidiary of Dignity Health is a healthcare service provider that offers physical therapy, rehabilitation and medical review. The center’s services include occupational medicine, urgent care, specialty care and therapy services. Its occup …
  • International Business Machines Corporation:企業の戦略・SWOT・財務情報
    International Business Machines Corporation - Strategy, SWOT and Corporate Finance Report Summary International Business Machines Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation …
  • Nippon Flour Mills Co Ltd (2001):企業の財務・戦略的SWOT分析
    Nippon Flour Mills Co Ltd (2001) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Magnolia Petroleum Plc (MAGP):企業の財務・戦略的SWOT分析
    Summary Magnolia Petroleum Plc (Magnolia Petroleum) is an oil and gas company. The company explores, acquires, and develops oil and natural gas properties. It holds interests in producing properties in two project areas such as Bakken shale in North Dakota and the proven Mississippi Lime, Woodford a …
  • Nobel Biocare Services AG:企業の戦略的SWOT分析
    Nobel Biocare Services AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Confluent Medical Technologies Inc:医療機器:M&Aディール及び事業提携情報
    Summary Confluent Medical Technologies Inc (CMT), formerly Nitinol Devices and Components Inc is a medical device company that manufactures and markets nitinol devices and balloon catheters. The company provides products such as wire, strip, sheet, tubing and bar, among others. It offers development …
  • Umeme Limited (UMEME):電力:M&Aディール及び事業提携情報
    Summary Umeme Limited (Umeme) is an electricity distribution utility. The company operates, maintains, upgrades, and expands the electricity distribution system in the country. It sources power from Uganda Electricity Transmission Company Limited which purchases energy from all independent power pro …
  • Schlumberger Limited:戦略・SWOT・企業財務分析
    Schlumberger Limited - Strategy, SWOT and Corporate Finance Report Summary Schlumberger Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • ConocoPhillips Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    ConocoPhillips Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary ConocoPhillips is an independent upstream oil and gas company. The company explore for, produce, transport and market crude oil, bitumen, natural gas, liquefied natural gas (LNG) and natural gas liqui …
  • Aptuit LLC-製薬・医療分野:企業M&A・提携分析
    Summary Aptuit LLC (Aptuit) is a provider of drug discovery and development services. The company offer wide range of services such as manufacturing, project management, small and large molecules analysis, formulation development, integrated chemistry, API route scouting and process development, con …
  • Reichhold LLC 2:企業の戦略的SWOT分析
    Reichhold LLC 2 - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Religare Enterprises Limited:企業のM&A・事業提携・投資動向
    Religare Enterprises Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Religare Enterprises Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • Ocular Therapeutix Inc (OCUL):企業の財務・戦略的SWOT分析
    Summary Ocular Therapeutix Inc (Ocular), formerly I-Therapeutix Inc is a biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for diseases using hydrogel platform technology. The company’s products include DEXTENZA, sustained release travoprost and posterior …
  • SonaCare Medical LLC:医療機器:M&Aディール及び事業提携情報
    Summary SonaCare Medical LLC (SonaCare Medical), formerly US HIFU LLC is a medical device company that manufactures ultrasound surgical ablation systems. The company's products comprise sonablate 450 and sonatherm. It develops technologies for urological indications providing procedures that control …
  • Celsius Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Celsius Therapeutics Inc (Celsius Therapeutics) is a biotechnology company that carries out single-cell genomic analysis to discover and develop precision medicines for autoimmune diseases and cancer. The company’s drug discovery is based on understanding specific cells that play a major rol …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆